2.23
+0.18(+8.78%)
Currency In USD
Address
One Cavendish Place
London, W1G 0QF
United Kingdom of Great Britain and Northern Ireland
Phone
44 33 3023 7300
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
April 24, 2019
| Name | Title | Pay | Year Born |
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer & Executive Director | 950,947 | 1959 |
| Ms. Christine Fox CPA | Chief Financial Officer | 624,447 | 1981 |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | 668,869 | 1969 |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development | 0 | 1965 |
| Mr. Bo Kara | Senior Vice President and Head of Pharmaceutical Development & CMC | 0 | N/A |
| Dr. John P. Richard M.B.A. | Co-Founder & Chief Business Officer | 0 | 1957 |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | 0 | 1952 |
| Dr. Jackie Parkin | Senior Vice President & Therapeutic Head | 0 | 1958 |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | 0 | 1971 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.